List of investigational sexual dysfunction drugs

Last updated

This is a list of investigational sexual dysfunction drugs, or drugs that are currently under development for clinical use for the treatment of sexual dysfunction but are not yet approved. Sexual function disorders include anorgasmia, atrophic vaginitis (vaginal atrophy), decreased libido, dyspareunia (painful sexual intercourse), erectile dysfunction, female sexual dysfunction (female sexual arousal disorder (FSAD)/hypoactive sexual desire disorder (HSSD)), male sexual dysfunction, premature ejaculation, vulvodynia (vulva pain), paraphilias, and hypersexuality, among others.

Contents

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]". The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications.

This list was last comprehensively updated in January 2026. It is likely to become outdated with time.

Under development

Preregistration

Phase 3

Phase 2

Phase 1/2

Phase 1

Clinical phase unknown

Preclinical

Phase unknown

Not under development

No development reported

Preregistration submission withdrawal

Suspended

Discontinued

Clinically used drugs

Approved drugs

Phosphodiesterase PDE5 inhibitors

  • Avanafil (Razatus; Spedra; Stendra; TA-1790; Zepeed) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Lodenafil (CRIS-031; Helleva) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Mirodenafil (Aibishi; Bravonto; Mvix; SK-3530) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Sildenafil (Revatio; Revatio IV; UK-92480; Viagra) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Sildenafil chewable tablets (Nurigra) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Sildenafil orally soluble film (sildenafil ODF; SPO-1101; Vultis) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Sildenafil orally soluble film (orodispersible sildenafil; Please; sildenafil oral dissolving film; sildenafil orally-disintegrating film; sildenafil OSF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Sildenafil oral spray (ASP-001; ASP-002; Bandol; Hezkue) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Sildenafil oro-dispersible tablets (Erecta; FACSID-50) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Simmerafil (Onvita; Onweida; semenafil; TPN-171; TPN-171-H) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Tadalafil (Adcirca; Cialis; GF-196960; IC-351; LY-450190; Zalutia) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Tadalafil oral disintegrating film (SPO-1102; Vulteum; tadalafil ODF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Tadalafil oral film (OGOOD) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Udenafil (DA-8159; Jurvigo; ME-3113; MZ101; Udzire; WC-3043; WC-3055; Zydena) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
  • Vardenafil (BAY-389456; Levitra; Nuviva; Staxyn; vardenafil ODT; vardenafil orodispersible tablet; Vivanza) – phosphodiesterase PDE5 inhibitor – erectile dysfunction

Prostaglandin E1 (PGE1) agonists

  • Alprostadil (Caverject; Prostaglandin E1) – prostaglandin E1 (PGE1) agonist – erectile dysfunction
  • Alprostadil alfadex (alprostadil alfadex complex; alprostadil-alpha-cyclodextrin; Edex; Prostaglandin E1-α-cyclodextrin complex; Prostandin; Prostavasin; Rigidur; Sugiran; Vasaprostan; Vasoprost; Viridal) – prostaglandin E1 (PGE1) agonist – erectile dysfunction
  • Alprostadil topical (Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Virirec; Vitaros; Vytaros; WC-3036) – prostaglandin E1 (PGE1) agonist – erectile dysfunction

Estrogens (estrogen receptor agonists)

  • Conjugated estrogens (conjugated equine estrogens; CEEs; Premarin) – estrogen (estrogen receptor agonist) – atrophic vaginitis, dyspareunia
  • Conjugated estrogens oral (Enjuvia; synthetic conjugated estrogens) – estrogen (estrogen receptor agonists) – atrophic vaginitis
  • Conjugated estrogens/bazedoxifene (Aprela; bazedoxifene acetate/conjugated estrogens; bazedoxifene/conjugated estrogens; bazedoxifene/Premarin; BZA/CE; CE/BZA; conjugated estrogens/bazedoxifene acetate; Duavee; Duavive; Premarin/bazedoxifene; SERM + Premarin) – combination of conjugated estrogens (estrogen) and bazedoxifene (selective estrogen receptor modulator (SERM)) – atrophic vaginitis
  • Estradiol (Estrofem; Innofem; oral estradiol; Vagifem; vaginal estradiol) – estrogen (estrogen receptor agonist) – atrophic vaginitis
  • Estradiol transdermal micro patch (Estradot; Minivelle; Vivelle-Dot) – estrogen (estrogen receptor agonist) – atrophic vaginitis
  • Estradiol vaginal (E2; 17β-estradiol; Estradiol VagiCap; Imvexxy; Joyesta; TX-12-004-HR; TX-004HR; VagiCap; Yuvvexy) – estrogen (estrogen receptor agonist) – atrophic vaginitis
  • Estradiol acetate (Estrace; estradiol acetate intravaginal ring; estradiol acetate IVR; Femring; Menoring) – estrogen (estrogen receptor agonist) – atrophic vaginitis
  • Estriol succinate vaginal gel (6α-hydroxyestradiol; Blissel; Gelistrol) – estrogen (estrogen receptor agonist) – atrophic vaginitis
  • Estriol/lactobacillus (estriol-Lactobcillus acidophilus mixt.; estriol/lyophilised lactobacilli; Gynoflor; ultra-low dose estrogen/lactobacillus) – combination of estriol (estrogen) and lactobacillus (probiotic) – atrophic vaginitis
  • Ospemifene (FC-1271a; Ophena; Osphena; Senshio) – selective estrogen receptor modulator (SERM) – atrophic vaginitis, dyspareunia

Other sex-hormonal agents

  • Prasterone vaginal (dehydroepiandrosterone; DHEA; Intrarosa; Vaginorm) – androgen (androgen receptor agonist), other actions – atrophic vaginitis, dyspareunia
  • Testosterone propionate (TP; Synandrol; Synerone) – androgen (androgen receptor agonist) – decreased libido
  • Tibolone (Livial) – androgen, estrogen, and progestogen – atrophic vaginitis, dyspareunia, low sexual desire [9] [10] [11] [12]
  • Triptorelin (Arvekap; AY-25650; BIM-21003; BN-52014; CL-118532; Debio-8200; Debio-8206; debio8200; Decapeptyl; Decapeptyl SR; Decapeptyl LP; Diphereline; Gonapeptyl; Moapar; Pamorelin; Pamorelin LA; Salvacyl; Trelstar; Trelstar Depot; Triptodur; Triptoreline; Tryptorelin; WY-42422) – gonadotropin-releasing hormone (GnRH) receptor agonist – paraphilias

Other drugs

  • Apomorphine (Ixense; Spontane; TAK-251; Uprima) – non-selective dopamine receptor agonist, other actions – erectile dysfunction
  • Bremelanotide (Rekynda; Vyleesi; PT-141) – melanocortin MC4 receptor agonist – female sexual dysfunction
  • Dapoxetine (LY-210448; LY210448; LY-210,448; Priligy) – selective serotonin reuptake inhibitor (SSRI) – premature ejaculation
  • Flibanserin (Addyi; BIMT-17; BIMT-17-BS; Girosa) – serotonin 5-HT1A receptor agonist, serotonin 5-HT2A receptor antagonist, other actions – female sexual dysfunction
  • Lidocaine/prilocaine (Fortacin; Prilocaine Lidocaine Plethora; prilocaine/lidocaine; PSD-502; Senstend; Tempe) – combination of lidocaine (sodium channel blocker, local anesthetic) and prilocaine (sodium channel blocker, local anesthetic) – premature ejaculation
  • Moxisylyte (thymoxamine) – α1-adrenergic receptor antagonist – erectile dysfunction [13]
  • Papaverine (Pavabid) – phosphodiesterase PDE10A inhibitor, other actions – erectile dysfunction [14] [15]
  • Phentolamine (Vasomax) – α1- and α2-adrenergic receptor antagonist – erectile dysfunction [16]

Combination drugs

Market withdrawal

Off-label drugs

Recreational drugs

See also

References

  1. ↑ Nappi RE, Tiranini L, Cucinella L, Martini E, Bosoni D, Righi A, Cassani C, Gardella B (January 2023). "Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?". Expert Opin Pharmacother. 24 (1): 135–143. doi:10.1080/14656566.2022.2066997. PMID   35430926. Ovoca Bio (Dublin, Ireland) is currently developing Orenetide (BP-101), a novel synthetic peptide, as a potential nasal spray for first-in-class treatment to stimulate sexual motivation [88]. Experimental placebo-controlled data showed that acute intranasal BP101 administration moderately increased the frequency of solicitations, an indicator of sexual motivation in female rats, by acting within the hypothalamus under different hormonal conditions [93]. A Phase 2, multicenter, double-blind, randomized, placebo-controlled trial is ongoing in New Zealand and Australia to demonstrate the efficacy and safety of different doses of BP101 in premenopausal women with HSDD [89].
  2. ↑ Both S (2017). "Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder". Curr Sex Health Rep. 9 (4): 192–199. doi:10.1007/s11930-017-0124-3. PMC   5711968 . PMID   29225554.
  3. ↑ Andreev-Andrievskiy A, Lomonosov M, Popova A, Lagereva E, Clément P, Salimov R, Golikov D (March 2017). "BP101 Peptide Promotes Female Sexual Receptivity in the Rat". J Sex Med. 14 (3): 336–346. doi:10.1016/j.jsxm.2017.01.008. PMID   28189563.
  4. ↑ Sukhikh, Sukhikh G.T.; Smulevich, Smulevich A.B.; Stenyaeva, Stenyaeva N.N.; Nemenov D, Nemenov D.G.; Prilepskaya, Prilepskaya V.N.; Khritinin, Khritinin D.F.; Myasoedov, Myasoedov N.F.; Matskevich A, Matskevich A.A.; Andreeva, Andreeva L.A.; V, E.V. Zelenina E.V.; Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia; Psychiatric Hospital No. 1 named after N.A. Alexeev, Department of Health of Moscow, Russia, Moscow; IVIX Ltd., Moscow, Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia; Institute of Molecular Genetics of National Research Centre «Kurchatov Institute», Moscow, Russia (30 August 2022). "Orenetide for the treatment of hypoactive sexual desire disorder: results of a randomized placebo-controlled trial". Akusherstvo I Ginekologiia. 8_2022: 95–106. doi:10.18565/aig.2022.8.95-106. ISSN   2412-5679 . Retrieved 27 January 2026.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
  5. ↑ Royston A, Gray; Laura M N, Sahyoun; Michelle, Kokkinou; Fraser R, Boistelle; Ryan, Protzko; Nigel, Gericke; Thomas, Pfeiffer (6 July 2023). "(52) KH-001 BUT NOT OTHER TESTED ALKALOIDS DERIVED FROM SCELETIUM TORTUOSUM DELAYS EJACULATION IN THE RAT PARA-CHLOROAMPHETAMINE (PCA) MODEL". The Journal of Sexual Medicine. 20 (Supplement_4) qdad062.002. doi:10.1093/jsxmed/qdad062.002. ISSN   1743-6095 . Retrieved 27 January 2026.
  6. ↑ Dr Gruss, H; Protzko, R; Woodfinden, L; Boghossian, J; Koch, A (9 December 2025). "(059) First-in Human Study Investigating KH-001 Besylate as a Novel On-Demand Treatment for Premature Ejaculation: Pharmacokinetic and Safety Evaluation". The Journal of Sexual Medicine. 22 (Supplement_4) qdaf320.059. doi:10.1093/jsxmed/qdaf320.059. ISSN   1743-6095 . Retrieved 27 January 2026.
  7. ↑ "Novel compounds and uses thereof". Google Patents. 22 July 2022. Retrieved 27 January 2026.
  8. ↑ McMahon CG (August 2016). "Emerging and investigational drugs for premature ejaculation". Transl Androl Urol. 5 (4): 487–501. doi: 10.21037/tau.2016.04.02 . PMC   5001989 . PMID   27652222.
  9. ↑ Albertazzi P, Di Micco R, Zanardi E (November 1998). "Tibolone: a review". Maturitas. 30 (3): 295–305. doi:10.1016/s0378-5122(98)00059-0. PMID   9881330.
  10. ↑ Pinto-Almazán R, Segura-Uribe JJ, Farfán-García ED, Guerra-Araiza C (2017). "Effects of Tibolone on the Central Nervous System: Clinical and Experimental Approaches". Biomed Res Int. 2017: 8630764. doi: 10.1155/2017/8630764 . PMC   5278195 . PMID   28191467.{{cite journal}}: CS1 maint: article number as page number (link)
  11. ↑ Biglia N, Maffei S, Lello S, Nappi RE (November 2010). "Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials". Gynecol Endocrinol. 26 (11): 804–814. doi:10.3109/09513590.2010.495437. PMID   20586550.
  12. ↑ Garefalakis M, Hickey M (2008). "Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence". Clin Interv Aging. 3 (1): 1–8. doi: 10.2147/cia.s1043 . PMC   2544356 . PMID   18488873.
  13. ↑ Marquer C, Bressolle F (1998). "Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence". Fundam Clin Pharmacol. 12 (4): 377–387. doi:10.1111/j.1472-8206.1998.tb00961.x. PMID   9711459.
  14. ↑ Rezaiezadeh H, Ranjbar Tavakoli M, Langarizadeh MA, Saeedi Garaghani Z, Karami-Mohajeri S (September 2024). "Unveiling the science behind erectile dysfunction topical therapy: investigating transdermal papaverine as a novel treatment approach". Sex Med Rev. 12 (4): 720–730. doi:10.1093/sxmrev/qeae059. PMID   39173091.
  15. 1 2 Zentgraf M, Baccouche M, Jünemann KP (1988). "Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine". Urol Int. 43 (2): 65–75. doi:10.1159/000281308. PMID   3291360.
  16. ↑ Goldstein I (March 2000). "Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction". Int J Impot Res. 12 Suppl 1: S75–80. doi:10.1038/sj.ijir.3900502. PMID   10845768.
  17. ↑ Baumbusch F, Papp GK, Kopa ZS (1995). "Treatment for potency problems with Afrodor 2000". Acta Chir Hung. 35 (1–2): 87–92. PMID   8659243.
  18. ↑ Jabir NR, Firoz CK, Zughaibi TA, Alsaadi MA, Abuzenadah AM, Al-Asmari AI, Alsaieedi A, Ahmed BA, Ramu AK, Tabrez S (December 2022). "A literature perspective on the pharmacological applications of yohimbine". Ann Med. 54 (1): 2861–2875. doi:10.1080/07853890.2022.2131330. PMC   9590431 . PMID   36263866.
  19. 1 2 Corazza O, Martinotti G, Santacroce R, Chillemi E, Di Giannantonio M, Schifano F, Cellek S (2014). "Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and Ginkgo biloba". Biomed Res Int. 2014: 841798. doi: 10.1155/2014/841798 . PMC   4082836 . PMID   25025070.{{cite journal}}: CS1 maint: article number as page number (link)
  20. ↑ Tam SW, Worcel M, Wyllie M (September 2001). "Yohimbine: a clinical review". Pharmacol Ther. 91 (3): 215–243. doi:10.1016/s0163-7258(01)00156-5. PMID   11744068.
  21. ↑ Morales A (August 2001). "Yohimbine in erectile dysfunction: would an orphan drug ever be properly assessed?". World J Urol. 19 (4): 251–255. doi:10.1007/s003450000182. PMID   11550783.
  22. 1 2 Cappelletti M, Wallen K (February 2016). "Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens". Horm Behav. 78: 178–193. doi:10.1016/j.yhbeh.2015.11.003. PMC   4720522 . PMID   26589379.
  23. ↑ Khan O, Ferriter M, Huband N, Powney MJ, Dennis JA, Duggan C (February 2015). "Pharmacological interventions for those who have sexually offended or are at risk of offending". Cochrane Database Syst Rev. 2015 (2): CD007989. doi:10.1002/14651858.CD007989.pub2. PMC   6544815 . PMID   25692326.{{cite journal}}: CS1 maint: article number as page number (link)
  24. 1 2 Assumpção AA, Garcia FD, Garcia HD, Bradford JM, Thibaut F (June 2014). "Pharmacologic treatment of paraphilias". Psychiatr Clin North Am. 37 (2): 173–181. doi:10.1016/j.psc.2014.03.002. PMID   24877704.
  25. 1 2 Guay DR (January 2009). "Drug treatment of paraphilic and nonparaphilic sexual disorders". Clin Ther. 31 (1): 1–31. doi:10.1016/j.clinthera.2009.01.009. PMID   19243704.
  26. 1 2 3 Sajith SG, Morgan C, Clarke D (December 2008). "Pharmacological management of inappropriate sexual behaviours: a review of its evidence, rationale and scope in relation to men with intellectual disabilities". J Intellect Disabil Res. 52 (12): 1078–1090. doi:10.1111/j.1365-2788.2008.01097.x. PMID   18557968.
  27. 1 2 Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R (January 2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clin Proc. 92 (1): 114–128. doi:10.1016/j.mayocp.2016.09.018. PMID   27916394.
  28. ↑ Razali NA, Sidi H, Choy CL, Roos NA, Baharudin A, Das S (2022). "The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis". Curr Neuropharmacol. 20 (10): 1941–1955. doi:10.2174/1570159X20666220222145735. PMC   9886814 . PMID   35193485.
  29. ↑ Pereira VM, Arias-Carrión O, Machado S, Nardi AE, Silva AC (2014). "Bupropion in the depression-related sexual dysfunction: a systematic review". CNS Neurol Disord Drug Targets. 13 (6): 1079–1088. doi:10.2174/1871527313666140612112630. PMID   24923342.
  30. ↑ Demyttenaere K, Jaspers L (September 2008). "Review: Bupropion and SSRI-induced side effects". J Psychopharmacol. 22 (7): 792–804. doi:10.1177/0269881107083798. PMID   18308785.
  31. ↑ Ginzburg R, Wong Y, Fader JS (December 2005). "Effect of bupropion on sexual dysfunction". Ann Pharmacother. 39 (12): 2096–2099. doi:10.1345/aph.1G275. PMID   16288071.
  32. ↑ Wu PC, Hung CS, Kang YN, Wu CC (February 2021). "Tolerability and Optimal Therapeutic Dosage of Clomipramine for Premature Ejaculation: A Systematic Review and Meta-Analysis". Sex Med. 9 (1): 100283. doi:10.1016/j.esxm.2020.10.011. PMC   7930847 . PMID   33291044.
  33. ↑ Choi JB, Kang SH, Lee DH, Kim YS, Jeon JS, Choi WS, Kim SW (January 2019). "Efficacy and Safety of On Demand Clomipramine for the Treatment of Premature Ejaculation: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial". J Urol. 201 (1): 147–152. doi:10.1016/j.juro.2018.07.089. PMID   30086277.
  34. ↑ Javanbakht A (February 2015). "As-needed use of cyproheptadine for treatment of selective serotonin reuptake inhibitor-related female anorgasmia". J Clin Psychopharmacol. 35 (1): 91–93. doi:10.1097/JCP.0000000000000260. PMID   25502486.
  35. ↑ Aizenberg D, Zemishlany Z, Weizman A (August 1995). "Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors". Clin Neuropharmacol. 18 (4): 320–324. doi:10.1097/00002826-199508000-00003. PMID   8665544.
  36. ↑ Badr B, Naguy A (October 2022). "Cyproheptadine: a psychopharmacological treasure trove?". CNS Spectr. 27 (5): 533–535. doi:10.1017/S1092852921000250. PMID   33632345.
  37. ↑ Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR (March 2016). "Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction". J Sex Med. 13 (3): 305–316. doi:10.1016/j.jsxm.2015.11.015. PMID   26944462.
  38. ↑ Cucinella L, Cassani C, Martini E, Parrotta GE, Monne G, Colombo GM, Morteo V, Nappi RE (September 2025). "Sexual function after menopause: the role of vaginal estrogens". Maturitas. 200 108681. doi:10.1016/j.maturitas.2025.108681. PMID   40743861.
  39. ↑ Auer MK, Joue G, Biedermann SV, Sommer T, Fuss J (February 2024). "The effect of short-term increase of estradiol levels on sexual desire and orgasm frequency in women and men: A double-blind, randomized, placebo-controlled trial". Psychoneuroendocrinology. 160 106682. doi:10.1016/j.psyneuen.2023.106682. PMID   38056372.
  40. ↑ Clayton AH, Campbell BJ, Favit A, Yang Y, Moonsammy G, Piontek CM, Amsterdam JD (December 2007). "Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale". J Clin Psychiatry. 68 (12): 1860–1866. doi:10.4088/jcp.v68n1205. PMID   18162016.
  41. ↑ Martyn-St James M, Cooper K, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L, Hood C (January 2015). "Tramadol for premature ejaculation: a systematic review and meta-analysis". BMC Urol. 15 6. doi: 10.1186/1471-2490-15-6 . PMC   4417346 . PMID   25636495.
  42. ↑ Kirby EW, Carson CC, Coward RM (July 2015). "Tramadol for the management of premature ejaculation: a timely systematic review". Int J Impot Res. 27 (4): 121–127. doi:10.1038/ijir.2015.7. PMID   25971856.
  43. ↑ Wong BL, Malde S (January 2013). "The use of tramadol "on-demand" for premature ejaculation: a systematic review". Urology. 81 (1): 98–103. doi:10.1016/j.urology.2012.08.037. PMID   23102445.
  44. ↑ Yang L, Qian S, Liu H, Liu L, Pu C, Han P, Wei Q (2013). "Role of tramadol in premature ejaculation: a systematic review and meta-analysis". Urol Int. 91 (2): 197–205. doi:10.1159/000348826. PMID   23751284.
  45. ↑ Sharma AP, Sharma G, Tyagi S, Devana SK, Mavuduru RS, Bora GS, Singh SK (2021). "Safety and efficacy of "on-demand" tramadol in patients with premature ejaculation: an updated meta-analysis". Int Braz J Urol. 47 (5): 921–934. doi:10.1590/S1677-5538.IBJU.2020.0561. PMC   8321462 . PMID   33566469.
  46. ↑ Wu T, Yue X, Duan X, Luo D, Cheng Y, Tian Y, Wang K (September 2012). "Efficacy and safety of tramadol for premature ejaculation: a systematic review and meta-analysis". Urology. 80 (3): 618–624. doi:10.1016/j.urology.2012.05.035. PMID   22840860.
  47. ↑ Tan H, Zhou Z, Cui Y, Feng F, Zhang Y (November 2021). "A systematic review and meta-analysis of randomized controlled trials of "on-demand" use of tramadol vs "on-demand" use of paroxetine in the management of patients with premature ejaculation". Int J Clin Pract. 75 (11): e14825. doi:10.1111/ijcp.14825. PMID   34492139.{{cite journal}}: CS1 maint: article number as page number (link)
  48. ↑ Pyke RE (April 2020). "Trazodone in Sexual Medicine: Underused and Overdosed?". Sex Med Rev. 8 (2): 206–216. doi:10.1016/j.sxmr.2018.08.003. PMID   30342856.
  49. ↑ Fink HA, MacDonald R, Rutks IR, Wilt TJ (September 2003). "Trazodone for erectile dysfunction: a systematic review and meta-analysis". BJU Int. 92 (4): 441–446. doi:10.1046/j.1464-410x.2003.04358.x. PMID   12930437.
  50. ↑ Bossini L, Casolaro I, Koukouna D, Cecchini F, Fagiolini A (August 2012). "Off-label uses of trazodone: a review". Expert Opin Pharmacother. 13 (12): 1707–1717. doi:10.1517/14656566.2012.699523. PMID   22712761.
  51. 1 2 3 4 5 6 7 Platteau, Tom; Schrooten, Jochen; Herrijgers, Corinne; den Daas, Chantal; Ventura, Mireia; Strong, Carol; de Wit, John (10 July 2025). "Polydrug use during chemsex: single and intersecting sexual effects of commonly used drugs". Frontiers in Public Health. 13 1618070. Bibcode:2025FrPH...1318070P. doi: 10.3389/fpubh.2025.1618070 . ISSN   2296-2565. PMC   12287032 . PMID   40709041.
  52. 1 2 3 4 5 6 Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardò FP (2017). "When "Chems" Meet Sex: A Rising Phenomenon Called "ChemSex"". Curr Neuropharmacol. 15 (5): 762–770. doi:10.2174/1570159X15666161117151148. PMC   5771052 . PMID   27855594.
  53. 1 2 3 Le Bouëdec D, Pelletier R, Bénézit F, Pangui R, Morel I, Gicquel T (November 2025). "Chemsex, drugs and consequences: A short review". Therapie. doi:10.1016/j.therap.2025.11.006. PMID   41381266.
  54. ↑ Georgiadis N, Katsimpris A, Vatmanidou MA, Vassilakou T, Beloukas A, Sergentanis TN (October 2025). "Prevalence of chemsex and sexualized drug use among men who have sex with men: A systematic review and meta-analysis". Drug Alcohol Depend. 275 112800. doi:10.1016/j.drugalcdep.2025.112800. PMID   40759067.
  55. ↑ Tomkins A, George R, Kliner M (January 2019). "Sexualised drug taking among men who have sex with men: a systematic review". Perspect Public Health. 139 (1): 23–33. doi:10.1177/1757913918778872. PMID   29846139.
  56. ↑ Trombley TA, Capstick RA, Lindsley CW (December 2020). "DARK Classics in Chemical Neuroscience: Gamma-Hydroxybutyrate (GHB)". ACS Chem Neurosci. 11 (23): 3850–3859. doi:10.1021/acschemneuro.9b00336. PMID   31287661.
  57. ↑ Mostafa T, Alghobary MF (July 2022). "Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight". Sex Med Rev. 10 (3): 392–402. doi:10.1016/j.sxmr.2021.10.004. PMID   34903486.
  58. ↑ Palamar JJ, Acosta P (January 2020). "A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines". Hum Psychopharmacol. 35 (1) e2719. doi:10.1002/hup.2719. PMC   6995261 . PMID   31909513.
  59. ↑ Nolan, James (2019-03-05). "This Is What 2-CB Does to You". Vice.com. Archived from the original on 11 November 2020. Retrieved 2021-10-03.
  60. ↑ Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628.
  61. ↑ Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN   0-9630096-9-9. OCLC   38503252.
  62. ↑ Araújo AM, Carvalho F, Bastos Mde L, Guedes de Pinho P, Carvalho M (August 2015). "The hallucinogenic world of tryptamines: an updated review" (PDF). Arch Toxicol. 89 (8): 1151–1173. Bibcode:2015ArTox..89.1151A. doi:10.1007/s00204-015-1513-x. PMID   25877327. Some studies also revealed that the use of tryptamine derivatives, especially of 5-MeO-DIPT, has come up very frequent among homosexual drug users (Clatts et al. 2005; Lee et al. 2013; Wada et al. 2013).
  63. ↑ Moyle L, Dymock A, Aldridge A, Mechen B (December 2020). "Pharmacosex: Reimagining sex, drugs and enhancement". Int J Drug Policy. 86 102943. doi:10.1016/j.drugpo.2020.102943. PMC   7773803 . PMID   33246312. Range of drugs and types of use [...] The same substances were broadly found as most commonly cited as enhancing sex in the virtual ethnography, although other substances, which interview participants sometimes lamented were difficult to access, included novel psychoactive substances such as 5-MeO-DIPT ('Foxy Methoxy').
  64. ↑ Miwa T, Strong C, Hayashi K, Yamaguchi M, Wakabayashi C, Ikushima Y (July 2025). "Drug Dependence Severity and Associated Factors Among Cisgender Gay, Bisexual and Other Men Who Have Sex With Men in Japan". J Psychoactive Drugs: 1–10. doi:10.1080/02791072.2025.2537044. PMID   40697137.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.